147 related articles for article (PubMed ID: 15342129)
1. Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene.
Craig D; Hart DJ; Carson R; McIlroy SP; Passmore AP
Neurosci Lett; 2004 Sep; 368(1):33-6. PubMed ID: 15342129
[TBL] [Abstract][Full Text] [Related]
2. The interleukin 1beta gene promoter polymorphism (-511) acts as a risk factor for psychosis in Alzheimer's dementia.
Craig D; Hart DJ; McCool K; McIlroy SP; Passmore AP
Ann Neurol; 2004 Jul; 56(1):121-4. PubMed ID: 15236409
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation in the G720/G30 gene locus (DAOA) influences the occurrence of psychotic symptoms in patients with Alzheimer's disease.
Di Maria E; Bonvicini C; Bonomini C; Alberici A; Zanetti O; Gennarelli M
J Alzheimers Dis; 2009; 18(4):953-60. PubMed ID: 20009237
[TBL] [Abstract][Full Text] [Related]
4. No association between neuregulin 1 and psychotic symptoms in Alzheimer's disease patients.
Middle F; Pritchard AL; Handoko H; Haque S; Holder R; Bentham P; Lendon CL
J Alzheimers Dis; 2010; 20(2):561-7. PubMed ID: 20182055
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer's type.
Sato N; Ueki A; Ueno H; Shinjo H; Morita Y
J Alzheimers Dis; 2009; 17(2):441-8. PubMed ID: 19363270
[TBL] [Abstract][Full Text] [Related]
6. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation.
Holmes C; Smith H; Ganderton R; Arranz M; Collier D; Powell J; Lovestone S
J Neurol Neurosurg Psychiatry; 2001 Dec; 71(6):777-9. PubMed ID: 11723200
[TBL] [Abstract][Full Text] [Related]
7. Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer's disease.
Pritchard AL; Ratcliffe L; Sorour E; Haque S; Holder R; Bentham P; Lendon CL
Int J Geriatr Psychiatry; 2009 Sep; 24(9):1020-5. PubMed ID: 19235789
[TBL] [Abstract][Full Text] [Related]
8. [Psychotic symptoms and Alzheimer's disease].
Alberca R; Gil-Néciga E; Salas D; Pérez JA; Lozano P
Neurologia; 2000 Jan; 15(1):8-14. PubMed ID: 10730061
[TBL] [Abstract][Full Text] [Related]
9. Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease.
Pritchard AL; Harris J; Pritchard CW; Coates J; Haque S; Holder R; Bentham P; Lendon CL
Neurobiol Aging; 2008 Mar; 29(3):341-7. PubMed ID: 17098333
[TBL] [Abstract][Full Text] [Related]
10. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease.
Sweet RA; Devlin B; Pollock BG; Sukonick DL; Kastango KB; Bacanu SA; Chowdari KV; DeKosky ST; Ferrell RE
Mol Psychiatry; 2005 Nov; 10(11):1026-36. PubMed ID: 16027741
[TBL] [Abstract][Full Text] [Related]
11. Psychotic symptoms in frontotemporal dementia: prevalence and review.
Mendez MF; Shapira JS; Woods RJ; Licht EA; Saul RE
Dement Geriatr Cogn Disord; 2008; 25(3):206-11. PubMed ID: 18204254
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis.
Ujike H; Katsu T; Okahisa Y; Takaki M; Kodama M; Inada T; Uchimura N; Yamada M; Iwata N; Sora I; Iyo M; Ozaki N; Kuroda S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Jun; 33(4):625-9. PubMed ID: 19275926
[TBL] [Abstract][Full Text] [Related]
14. No association between the dopamine D3 receptor Bal I polymorphism and schizophrenia in a family-based study of a Palestinian Arab population.
Kremer I; Rietschel M; Dobrusin M; Mujaheed M; Murad I; Blanaru M; Bannoura I; Müller DJ; Schulze TG; Reshef A; Gathas S; Schwab S; Wildenauer D; Bachner-Melman R; Belmaker RH; Maier W; Ebstein RP
Am J Med Genet; 2000 Dec; 96(6):778-80. PubMed ID: 11121180
[TBL] [Abstract][Full Text] [Related]
15. Trend for an association between schizophrenia and D3S1310, a marker in proximity to the dopamine D3 receptor gene.
Jönsson EG; Nimgaonkar VL; Zhang XR; Shaw SH; Burgert E; Crocq MA; Chakravarti A; Sedvall GC
Am J Med Genet; 1999 Aug; 88(4):352-7. PubMed ID: 10402502
[TBL] [Abstract][Full Text] [Related]
16. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients.
Pritchard AL; Pritchard CW; Bentham P; Lendon CL
Dement Geriatr Cogn Disord; 2007; 24(3):201-6. PubMed ID: 17690552
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D3 receptor gene not associated with symptomatology of major psychoses.
Serretti A; Lattuada E; Cusin C; Lilli R; Lorenzi C; Smeraldi E
Am J Med Genet; 1999 Oct; 88(5):476-80. PubMed ID: 10490702
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer's disease.
Pritchard AL; Pritchard CW; Bentham P; Lendon CL
Dement Geriatr Cogn Disord; 2008; 26(3):257-60. PubMed ID: 18841010
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation in the 5-HT2A receptor and altered neocortical [3H] ketanserin binding in Alzheimer's disease.
Holmes C; McCulley M; Nicoll JA; Alder JT; Chen CP; Francis PT
Neurosci Lett; 2007 Jun; 420(1):58-60. PubMed ID: 17481814
[TBL] [Abstract][Full Text] [Related]
20. Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study.
Grünblatt E; Zehetmayer S; Bartl J; Löffler C; Wichart I; Rainer MK; Jungwirth S; Bauer P; Danielczyk W; Tragl KH; Riederer P; Fischer P
J Psychiatr Res; 2009 Jan; 43(3):298-308. PubMed ID: 18603262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
